01—Abstract
Summary
Summary of the 8-K filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Emerson Electric (EMR) reported fiscal Q4 and full-year 2025 results (year ended September 30, 2025) and issued initial fiscal 2026 guidance.
Q4 net sales rose 5% reported and 4% underlying to $4.855Ba, with underlying orders up 4%. Full-year net sales reached $18.016B (+3% reported and underlying). Profitability improved meaningfully: full-year adjusted segment EBITA margin expanded 160 bps to 27.6%, GAAP pretax margin rose to 16.3% from 11.5% (largely because the prior year absorbed Copeland note loss, inventory step-up and other one-time items), and adjusted EPS grew 9% to $6.00.
GAAP EPS from continuing operations rose 43% to $4.03b. Cash generation was strong, with free cash flow up 12% to $3.245B. The more significant capital allocation shift is the pivot to shareholder returns.
The Board authorized a new repurchase program of up to 50 million shares, on top of roughly 20 million shares remaining under the 2020 authorization. The 2026 outlook assumes about $2.2Bc returned to shareholders, comprising roughly $1.0B of buybacks and $1.2B of dividends, and the quarterly dividend is raised 5% to $0.555. The balance sheet shows the effects of the AspenTech buy-in: cash fell to $1.5B, short-term debt rose to $4.8B, and noncontrolling interests dropped from $5.9B to nearly zero after the $7.2B purchase.
Total equity declined to $20.3Bd. Fiscal 2026 guidance calls for net sales growth of about 5.5% (about 4% underlying), adjusted EPS of $6.35 to $6.55 and GAAP EPS of $4.73 to $4.93, with free cash flow of $3.5B to $3.6B.
Management highlighted mid-single-digit underlying orders growth for three consecutive quarters and the completion of AspenTech and Test & Measurement integration, with $200M of run-rate cost synergies targeted. Investors should note that the 2026 outlook depends on sustained order momentum, and that the Test & Measurement and Control Systems & Software segments drove much of the recent margin expansion.
02—Key points
Key Highlights
- Q4 FY25 net sales of $4.855B (+5% reported, +4% underlying); underlying orders +4%, following mid-single-digit growth for three consecutive quarters
- FY25 adjusted EPS of $6.00 (+9%) and GAAP EPS from continuing operations of $4.03 (+43%); adjusted segment EBITA margin expanded 160 bps to 27.6%
- FY25 free cash flow of $3.245B (+12%); operating cash flow of $3.676B from continuing operations
- New authorization to repurchase up to 50M shares, in addition to ~20M remaining under the 2020 program
- Quarterly dividend raised 5% to $0.555 per share, payable December 10, 2025
- FY26 guidance: net sales growth ~5.5% (~4% underlying), adjusted EPS $6.35–$6.55, free cash flow $3.5–$3.6B, and ~$2.2B returned to shareholders (~$1.0B buybacks, ~$1.2B dividends)
- Balance sheet shifted after the AspenTech buy-in: cash fell to $1.5B from $3.6B, short-term debt rose to $4.8B, and noncontrolling interests dropped to $16M from $5.9B
03—Questions
Frequently Asked Questions
How did Emerson perform in the fourth quarter and full year of fiscal 2025?
Q4 net sales were $4.855B, up 5% reported and 4% underlying, with adjusted EPS of $1.62 (+9%). For the full year, net sales were $18.016B (+3%), adjusted EPS was $6.00 (+9%), and free cash flow was $3.245B (+12%). Adjusted segment EBITA margin improved to 27.6% for the year.
Why did GAAP pretax margin jump so sharply in fiscal 2025?
GAAP pretax margin rose to 16.3% from 11.5%, largely because fiscal 2024 included about $279M for the Copeland note receivable loss, $231M of acquisition-related inventory step-up amortization, and $79M of gains on subordinated interest, none of which recurred in 2025. Amortization of intangibles also fell to $1.08B from $1.27B.
What does the new share repurchase authorization mean for shareholders?
The Board authorized repurchases of up to 50M shares over several years, with about 20M remaining under the 2020 program. The 2026 plan targets roughly $1.0B of buybacks, plus about $1.2B of dividends. Timing and amounts will depend on market conditions, and the program can be suspended at any time, so the 2026 buyback figure is the more concrete indicator.
What is the 2026 outlook and what are the main risks?
Guidance calls for net sales growth of ~5.5% (about 4% underlying), GAAP EPS of $4.73–$4.93, adjusted EPS of $6.35–$6.55, and free cash flow of $3.5–$3.6B. Risks cited in the filing include global conflicts, currency and economic conditions, market demand, tariffs, competition, inflation and cybersecurity. Guidance assumes a sustained recovery in orders and continued integration progress, and a Q1 underlying growth of only ~2% signals a slower start.
How has Emerson's balance sheet changed after the AspenTech transaction?
Following the approximately $7.2B purchase of the noncontrolling interest in AspenTech, cash fell to $1.5B from $3.6B and short-term borrowings and current debt rose to $4.8B from $532M. Long-term debt increased to $8.3B from $7.2B. Total equity declined to $20.3B from $27.5B, largely because of the reduction in noncontrolling interests, so leverage and interest expense (up to $237M from $175M) warrant monitoring as the company returns cash to shareholders.
04—Continue